Light chain multiple myeloma, clinic features, responses to therapy and survival in a long-term study.

Abstract

BACKGROUND:

We intended to investigate the long-term clinical characteristics, responses to therapy and survival in patients with lightchain multiple myeloma (MM).

METHODS:

Ninety-six patients were enrolled into the study. There were 42 κ-chain MM patients and 54 λ-chain MM patients. All the patients werestage III in the Durie-Salmonstaging system. Among them, 66 patients received Velcade (bortezomib) treatment and the other 30 did not.

RESULTS:

The main symptoms of these patients included bone pain (77.1%), weakness and fatigue (12.5%), foamy urine (8.3%) and extramedullaryplasmocytomas (33.3%). The overall response rate (ORR) was 95.5% in patients treated with Velcade and 60%in the patients without. The median survival times were 23 months in patients treated with Velcade and 12 months in patients without. The median time of progression-free survival (PFS) was nine months in patients treated with Velcade and five months in patients without. The one-year PFS and two-year PFS were 37% and 25%, 27% and 9% for patients treated with Velcade, or without, respectively. The three-year overall survival (OS) and five-year OS were 33% and 24%, 28% and 9% for patients treated with Velcade, or without, respectively. There was no significance in OS between the two groups (P = 0.335). But there was significant difference in PFS between the two groups (P = 0.036).

CONCLUSIONS:

Our long-term study demonstrated that patients with lightchain myeloma appeared to have more aggressive disease courses and poor outcomes, which could be improved by treatment with Velcade.

• Authors: Jia-jia Zhang, Wan-jun Sun, Zhong-xia Huang, Shi-lun Chen, Yu-ping Zhong, Ying Hu, Na An, Men Shen, Xin Li
• Journal: World journal of surgical oncology (World J Surg Oncol) Vol. 12 Pg. 234 (Jul 28 2014) ISSN: 1477-7819 [Electronic] England
• PMID: 25070574 (Publication Type: Journal Article)

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Female
• Follow-Up Studies
• Humans
• Longitudinal Studies
• Male
• Middle Aged
• Multiple Myeloma (drug therapy, mortality, pathology)
• Neoplasm Staging
• Prognosis
• Survival Rate